AXGN:NASDAQ
AxoGen, Inc Common Stock
၅၅.၉၃ US$
arrow_upward
+၀.၉၆%(+၀.၅၃) 1D
၅၅.၅၀ US$
arrow_downward
-၀.၇၇% (-၀.၄၃)bedtimeAfter hours
Closed: နို ၁၃, GMT-၅ ၁၆:၀၀:၀၁ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
၅၅.၈၈ US$
High
၅၇.၄၆ US$
Low
၅၅.၀၁ US$
Mkt. cap
၃၃၄.၀၇ ဋေ
Avg. vol.
၁.၉၈ သန်း
Volume
၁.၃၈ သန်း
52-wk high
၅၉.၇၂ US$
52-wk low
၂၃.၀၀ US$
EPS
-၀.၆၈ US$
Beta
၁.၂၁
Shares outstanding
၅.၉၇ ကုဋေ
No. of employees
၆၂၂
Open
၅၅.၈၈ US$
High
၅၇.၄၆ US$
Low
၅၅.၀၁ US$
Mkt. cap
၃၃၄.၀၇ ဋေ
Avg. vol.
၁.၉၈ သန်း
Volume
၁.၃၈ သန်း
52-wk high
၅၉.၇၂ US$
52-wk low
၂၃.၀၀ US$
EPS
-၀.၆၈ US$
Beta
၁.၂၁
Shares outstanding
၅.၉၇ ကုဋေ
No. of employees
၆၂၂
News stories
From web sources and news partners
Zacks
·
ပြီးခဲ့သည့် ၁ ရက်
AxoGen (AXGN) is a Great Momentum Stock: Should You Buy?
Investing.com
·
ပြီးခဲ့သည့် ၂ ရက်
AxoGen at Canaccord forum: growth plan widens beyond nerve repair
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees၆၂၂
Founded၂၀၀၂
HeadquartersAlachua, ဖလော်ရီဒါပြည်နယ်, ယူနိုက်တက်စတိတ်
SectorHealth Care
Industry-
Websiteaxogeninc.com